Ethypharm Announces the Appointment of Dan Tovar to the Position of Executive Vice-President Medical Affairs and Drug Development

ST CLOUD, France, October 2, 2017 /PRNewswire/ --

Ethypharm announces the appointment of Dan Tovar to the position of Executive Vice-President Medical Affairs and Drug Development.

     (Logo: http://mma.prnewswire.com/media/565951/Ethypharm_Logo.jpg )

A pharmacist by training, Dan worked as a lecturer at the Paul Sabatier University in Toulouse and as a researcher in the Health and Medical Research Institute of the Toulouse cancer research centre between 2003 and 2007.

He left the world of scientific and academic research in 2008 to join Janssen. Having held various medical affair positions of increasing responsibility, he was appointed Medical Director of Oncological Haematology in 2015 and at the same time was acting head of Medical Affairs for Janssen France between May 2016 and May 2017.

Ethypharm is delighted to welcome Dan into the Ethypharm Group where he has already started as Executive Vice-President Medical Affairs and Drug Development.

"I have always been professionally committed to finding answers for unmet medical needs, benefiting both patients with serious diseases and the doctors who treat them. I am joining Ethypharm with great determination to make a success of the development of new products with added medical value for patients and clinicians", said Dan Tovar.

Hugues Lecat, CEO of Group Ethypharm, says "One of the strengths of Ethypharm is the ability to develop our own medicinal products. Dan's arrival provides us with scientific and medical expertise and puts us in close touch with health care experts, so that we can get to know patients' needs as well as possible."

About Ethypharm 

Ethypharm is a European-based specialty pharmaceutical company with global reach and a committed player in the treatment of pain and addiction. Ethypharm also develops and markets complex generics and essential medicines that help reduce healthcare costs, particularly in the field of emergency care and oncology. The Company employs 1400 people mainly in Europe, and its drugs are marketed in more than 50 countries. Our ambition is to become the European leader for the treatment of pain and addiction, and to help patients around the world gain access to high quality, essential and affordable medicines.

Press contact - Greta Guzman, presse@ethypharm.com , +33-(0)-1-41-12-17-20